Sackner-Bernstein JD - Search Results

1

Rationale for treatment of patients with chronic heart failure with adrenergic blockade.

Sackner-Bernstein JD, Mancini DM. Sackner-Bernstein JD, et al. JAMA. 1995 Nov 8;274(18):1462-7. JAMA. 1995. PMID: 7474194 Review.

2

New evidence from the CAPRICORN Trial: the role of carvedilol in high-risk, post-myocardial infarction patients.

Sackner-Bernstein JD. Sackner-Bernstein JD. Rev Cardiovasc Med. 2003;4 Suppl 3:S25-9. Rev Cardiovasc Med. 2003. PMID: 14564231 Review.

3

FDA Approval of Eteplirsen for Muscular Dystrophy.

Sackner-Bernstein J. Sackner-Bernstein J. JAMA. 2017 Apr 11;317(14):1480-1481. doi: 10.1001/jama.2017.2597. JAMA. 2017. PMID: 28399244 No abstract available.

4

Risk of death associated with nesiritide in patients with acutely decompensated heart failure.

Aaronson KD, Sackner-Bernstein J. Aaronson KD, et al. JAMA. 2006 Sep 27;296(12):1465-6. doi: 10.1001/jama.296.12.1465. JAMA. 2006. PMID: 17003394 No abstract available.

5

Nesiritide for acute decompensated heart failure: does the benefit justify the risk?

Sackner-Bernstein J, Aaronson KD. Sackner-Bernstein J, et al. Curr Cardiol Rep. 2007 May;9(3):187-93. doi: 10.1007/BF02938349. Curr Cardiol Rep. 2007. PMID: 17470331 Review.

6

Use of carvedilol in chronic heart failure: challenges in therapeutic management.

Sackner-Bernstein JD. Sackner-Bernstein JD. Prog Cardiovasc Dis. 1998 Jul-Aug;41(1 Suppl 1):53-8. doi: 10.1016/s0033-0620(98)80031-5. Prog Cardiovasc Dis. 1998. PMID: 9715823 Review.

7

Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. US Carvedilol Heart Failure Study Group.

Colucci WS, Packer M, Bristow MR, Gilbert EM, Cohn JN, Fowler MB, Krueger SK, Hershberger R, Uretsky BF, Bowers JA, Sackner-Bernstein JD, Young ST, Holcslaw TL, Lukas MA. Colucci WS, et al. Circulation. 1996 Dec 1;94(11):2800-6. doi: 10.1161/01.cir.94.11.2800. Circulation. 1996. PMID: 8941105 Clinical Trial.

8

Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure. The PRECISE Trial. Prospective Randomized Evaluation of Carvedilol on Symptoms and Exercise.

Packer M, Colucci WS, Sackner-Bernstein JD, Liang CS, Goldscher DA, Freeman I, Kukin ML, Kinhal V, Udelson JE, Klapholz M, Gottlieb SS, Pearle D, Cody RJ, Gregory JJ, Kantrowitz NE, LeJemtel TH, Young ST, Lukas MA, Shusterman NH. Packer M, et al. Circulation. 1996 Dec 1;94(11):2793-9. doi: 10.1161/01.cir.94.11.2793. Circulation. 1996. PMID: 8941104 Clinical Trial.

9

Double-blind, placebo-controlled study of the long-term efficacy of carvedilol in patients with severe chronic heart failure.

Krum H, Sackner-Bernstein JD, Goldsmith RL, Kukin ML, Schwartz B, Penn J, Medina N, Yushak M, Horn E, Katz SD, et al. Krum H, et al. Circulation. 1995 Sep 15;92(6):1499-506. doi: 10.1161/01.cir.92.6.1499. Circulation. 1995. PMID: 7664433 Clinical Trial.

10

The myocardial matrix and the development and progression of ventricular remodeling.

Sackner-Bernstein JD. Sackner-Bernstein JD. Curr Cardiol Rep. 2000 Mar;2(2):112-9. doi: 10.1007/s11886-000-0007-4. Curr Cardiol Rep. 2000. PMID: 10980881 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results